The Purkinje fibres have the fastest conduction velocities in the heart, reaching about 4m/sec. During cardiac electrical activation, the SA node generates action potentials that spread throughout the atria muscle during atrial systole, conducting at a velocity of approximately 0.5m/sec. The atrioventricular node acts as a pathway for action potentials to enter from the atria to the ventricles, also conducting at a similar velocity of about 0.5m/sec. The Bundle of His, located at the base of the ventricle, divides into the left and right bundle branches, which conduct at a faster velocity of around 2m/sec. These bundles then divide into an extensive system of Purkinje fibres that conduct the impulse throughout the ventricles at an even faster velocity of about 4m/sec.

Understanding the Cardiac Action Potential and Conduction Velocity

The cardiac action potential is a series of electrical events that occur in the heart during each heartbeat. It is responsible for the contraction of the heart muscle and the pumping of blood throughout the body. The action potential is divided into five phases, each with a specific mechanism. The first phase is rapid depolarization, which is caused by the influx of sodium ions. The second phase is early repolarization, which is caused by the efflux of potassium ions. The third phase is the plateau phase, which is caused by the slow influx of calcium ions. The fourth phase is final repolarization, which is caused by the efflux of potassium ions. The final phase is the restoration of ionic concentrations, which is achieved by the Na+/K+ ATPase pump.

Conduction velocity is the speed at which the electrical signal travels through the heart. The speed varies depending on the location of the signal. Atrial conduction spreads along ordinary atrial myocardial fibers at a speed of 1 m/sec. AV node conduction is much slower, at 0.05 m/sec. Ventricular conduction is the fastest in the heart, achieved by the large diameter of the Purkinje fibers, which can achieve velocities of 2-4 m/sec. This allows for a rapid and coordinated contraction of the ventricles, which is essential for the proper functioning of the heart. Understanding the cardiac action potential and conduction velocity is crucial for diagnosing and treating heart conditions.

Rheumatic heart fever is characterized by the presence of Aschoff bodies, which are granulomatous nodules. The mitral valve is commonly affected in this condition, and an elevated ASO titre indicates exposure to group A streptococcus bacteria. Rheumatic heart disease is also associated with the presence of Anitschkow cells, which are enlarged macrophages with an ovoid, wavy, rod-like nucleus. Other types of bodies seen in different conditions include Councilman bodies in hepatitis C and yellow fever, Mallory bodies in alcoholism affecting hepatocytes, and Call-Exner bodies in granulosa cell tumours.

Rheumatic fever is a condition that occurs as a result of an immune response to a recent Streptococcus pyogenes infection, typically occurring 2-4 weeks after the initial infection. The pathogenesis of rheumatic fever involves the activation of the innate immune system, leading to antigen presentation to T cells. B and T cells then produce IgG and IgM antibodies, and CD4+ T cells are activated. This immune response is thought to be cross-reactive, mediated by molecular mimicry, where antibodies against M protein cross-react with myosin and the smooth muscle of arteries. This response leads to the clinical features of rheumatic fever, including Aschoff bodies, which are granulomatous nodules found in rheumatic heart fever.

To diagnose rheumatic fever, evidence of recent streptococcal infection must be present, along with 2 major criteria or 1 major criterion and 2 minor criteria. Major criteria include erythema marginatum, Sydenham’s chorea, polyarthritis, carditis and valvulitis, and subcutaneous nodules. Minor criteria include raised ESR or CRP, pyrexia, arthralgia, and prolonged PR interval.

Management of rheumatic fever involves antibiotics, typically oral penicillin V, as well as anti-inflammatories such as NSAIDs as first-line treatment. Any complications that develop, such as heart failure, should also be treated. It is important to diagnose and treat rheumatic fever promptly to prevent long-term complications such as rheumatic heart disease.

Naftidrofuryl, a 5-HT2 receptor antagonist, can be used to treat peripheral vascular disease (PVD) and alleviate symptoms such as intermittent claudication. This medication works by causing vasodilation, which increases blood flow to areas of the body affected by PVD. On the other hand, drugs like doxazosin, an alpha 1 blocker, do not have a role in treating PVD. Beta blockers, which can worsen intermittent claudication by inducing vasoconstriction, are also not recommended for PVD treatment.

Managing Peripheral Arterial Disease

Peripheral arterial disease (PAD) is closely associated with smoking, and patients who still smoke should be provided with assistance to quit. Comorbidities such as hypertension, diabetes mellitus, and obesity should also be treated. All patients with established cardiovascular disease, including PAD, should be taking a statin, with atorvastatin 80 mg currently recommended. In 2010, NICE recommended clopidogrel as the first-line treatment for PAD patients over aspirin.

Exercise training has been shown to have significant benefits, and NICE recommends a supervised exercise program for all PAD patients before other interventions. Severe PAD or critical limb ischaemia may be treated with endovascular or surgical revascularization, with endovascular techniques typically used for short segment stenosis, aortic iliac disease, and high-risk patients. Surgical techniques are typically used for long segment lesions, multifocal lesions, lesions of the common femoral artery, and purely infrapopliteal disease. Amputation should be reserved for patients with critical limb ischaemia who are not suitable for other interventions such as angioplasty or bypass surgery.

Drugs licensed for use in PAD include naftidrofuryl oxalate, a vasodilator sometimes used for patients with a poor quality of life, and cilostazol, a phosphodiesterase III inhibitor with both antiplatelet and vasodilator effects, which is not recommended by NICE.

Ramipril is the correct medication for this patient with likely chronic heart failure. It is one of the few drugs that has been shown to improve the overall prognosis of heart failure, along with beta-blockers and aldosterone antagonists. Aspirin, digoxin, and furosemide are commonly used in the management of heart failure but do not offer prognostic benefit.

Chronic heart failure can be managed through drug treatment, according to updated guidelines issued by NICE in 2018. While loop diuretics are useful in managing fluid overload, they do not reduce mortality in the long term. The first-line treatment for all patients is a combination of an ACE-inhibitor and a beta-blocker, with clinical judgement used to determine which one to start first. Aldosterone antagonists are recommended as second-line treatment, but potassium levels should be monitored as both ACE inhibitors and aldosterone antagonists can cause hyperkalaemia. Third-line treatment should be initiated by a specialist and may include ivabradine, sacubitril-valsartan, hydralazine in combination with nitrate, digoxin, and cardiac resynchronisation therapy. Other treatments include annual influenzae and one-off pneumococcal vaccines. Those with asplenia, splenic dysfunction, or chronic kidney disease may require a booster every 5 years.

Localisation of Myocardial Infarction

Myocardial infarction (MI) is a medical emergency that occurs when there is a blockage in the blood flow to the heart muscle. The location of the blockage determines the type of MI and the treatment required. An inferior MI is caused by the occlusion of the right coronary artery, which supplies blood to the bottom of the heart. This type of MI can cause symptoms such as chest pain, shortness of breath, and nausea. It is important to identify the location of the MI quickly to provide appropriate treatment and prevent further damage to the heart muscle. Proper diagnosis and management can improve the patient’s chances of survival and reduce the risk of complications.

Furosemide is a medication that is often prescribed to patients with heart failure who have excess fluid in their bodies. It works by inhibiting the Na-K-Cl cotransporter in the thick ascending limb of the loop of Henle, which prevents the reabsorption of sodium. This results in a less hypertonic renal medulla and reduces the osmotic force that causes water to be reabsorbed from the collecting ducts. As a result, more water is excreted through the kidneys.

It is important to be aware of the common side effects of loop diuretics, which are listed in the notes below.

Loop Diuretics: Mechanism of Action and Clinical Applications

Loop diuretics, such as furosemide and bumetanide, are medications that inhibit the Na-K-Cl cotransporter (NKCC) in the thick ascending limb of the loop of Henle. By doing so, they reduce the absorption of NaCl, resulting in increased urine output. Loop diuretics act on NKCC2, which is more prevalent in the kidneys. These medications work on the apical membrane and must first be filtered into the tubules by the glomerulus before they can have an effect. Patients with poor renal function may require higher doses to ensure sufficient concentration in the tubules.

Loop diuretics are commonly used in the treatment of heart failure, both acutely (usually intravenously) and chronically (usually orally). They are also indicated for resistant hypertension, particularly in patients with renal impairment. However, loop diuretics can cause adverse effects such as hypotension, hyponatremia, hypokalemia, hypomagnesemia, hypochloremic alkalosis, ototoxicity, hypocalcemia, renal impairment, hyperglycemia (less common than with thiazides), and gout. Therefore, careful monitoring of electrolyte levels and renal function is necessary when using loop diuretics.

The superficial fascia of the posterior triangle contains the external jugular vein, which runs diagonally and drains into the subclavian vein. Surgeons must be careful during exploration of this area to avoid injuring the external jugular vein and causing excessive bleeding. The internal jugular vein and carotid arteries are located in the anterior triangle, while the third part of the subclavian artery is found in the posterior triangle, not the second part.

The posterior triangle of the neck is an area that is bound by the sternocleidomastoid and trapezius muscles, the occipital bone, and the middle third of the clavicle. Within this triangle, there are various nerves, vessels, muscles, and lymph nodes. The nerves present include the accessory nerve, phrenic nerve, and three trunks of the brachial plexus, as well as branches of the cervical plexus such as the supraclavicular nerve, transverse cervical nerve, great auricular nerve, and lesser occipital nerve. The vessels found in this area are the external jugular vein and subclavian artery. Additionally, there are muscles such as the inferior belly of omohyoid and scalene, as well as lymph nodes including the supraclavicular and occipital nodes.

Hypotension, particularly on the first dose, and deterioration of renal function are common side effects of ACE inhibitors in patients. Although angioedema is a rare side effect of ACE inhibitors, oedema is typically associated with calcium channel blockers. Diuretics may cause excessive urine output, while shortness of breath and headaches are uncommon.

Angiotensin-converting enzyme (ACE) inhibitors are commonly used as the first-line treatment for hypertension and heart failure in younger patients. However, they may not be as effective in treating hypertensive Afro-Caribbean patients. ACE inhibitors are also used to treat diabetic nephropathy and prevent ischaemic heart disease. These drugs work by inhibiting the conversion of angiotensin I to angiotensin II and are metabolized in the liver.

While ACE inhibitors are generally well-tolerated, they can cause side effects such as cough, angioedema, hyperkalaemia, and first-dose hypotension. Patients with certain conditions, such as renovascular disease, aortic stenosis, or hereditary or idiopathic angioedema, should use ACE inhibitors with caution or avoid them altogether. Pregnant and breastfeeding women should also avoid these drugs.

Patients taking high-dose diuretics may be at increased risk of hypotension when using ACE inhibitors. Therefore, it is important to monitor urea and electrolyte levels before and after starting treatment, as well as any changes in creatinine and potassium levels. Acceptable changes include a 30% increase in serum creatinine from baseline and an increase in potassium up to 5.5 mmol/l. Patients with undiagnosed bilateral renal artery stenosis may experience significant renal impairment when using ACE inhibitors.

The current NICE guidelines recommend using a flow chart to manage hypertension, with ACE inhibitors as the first-line treatment for patients under 55 years old. However, individual patient factors and comorbidities should be taken into account when deciding on the best treatment plan.

The ST segment on an ECG indicates the period when the entire ventricle is depolarized. In the case of a suspected myocardial infarction, it is crucial to examine the ST segment for any elevation or depression, which can indicate a STEMI or NSTEMI, respectively.

The ECG does not have a specific section that corresponds to the firing of the sino-atrial node, which triggers atrial depolarization (represented by the p wave). The T wave represents ventricular repolarization.

In atrial fibrillation, the p wave is absent or abnormal due to the irregular firing of the atria.

Understanding the Normal ECG

The electrocardiogram (ECG) is a diagnostic tool used to assess the electrical activity of the heart. The normal ECG consists of several waves and intervals that represent different phases of the cardiac cycle. The P wave represents atrial depolarization, while the QRS complex represents ventricular depolarization. The ST segment represents the plateau phase of the ventricular action potential, and the T wave represents ventricular repolarization. The Q-T interval represents the time for both ventricular depolarization and repolarization to occur.

The P-R interval represents the time between the onset of atrial depolarization and the onset of ventricular depolarization. The duration of the QRS complex is normally 0.06 to 0.1 seconds, while the duration of the P wave is 0.08 to 0.1 seconds. The Q-T interval ranges from 0.2 to 0.4 seconds depending upon heart rate. At high heart rates, the Q-T interval is expressed as a ‘corrected Q-T (QTc)’ by taking the Q-T interval and dividing it by the square root of the R-R interval.

Understanding the normal ECG is important for healthcare professionals to accurately interpret ECG results and diagnose cardiac conditions. By analyzing the different waves and intervals, healthcare professionals can identify abnormalities in the electrical activity of the heart and provide appropriate treatment.

The ligamentum arteriosum is what remains of the ductus arteriosus after it typically closes at birth. If the ductus arteriosus remains open, known as a patent ductus arteriosus, it can cause infants to fail to thrive. The ventricles of the heart come from the bulbus cordis and primitive ventricle. The coronary sinus is formed by a group of cardiac veins merging together. The ligamentum venosum is the leftover of the ductus venosum. The fossa ovalis is created when the foramen ovale closes.

During cardiovascular embryology, the heart undergoes significant development and differentiation. At around 14 days gestation, the heart consists of primitive structures such as the truncus arteriosus, bulbus cordis, primitive atria, and primitive ventricle. These structures give rise to various parts of the heart, including the ascending aorta and pulmonary trunk, right ventricle, left and right atria, and majority of the left ventricle. The division of the truncus arteriosus is triggered by neural crest cell migration from the pharyngeal arches, and any issues with this migration can lead to congenital heart defects such as transposition of the great arteries or tetralogy of Fallot. Other structures derived from the primitive heart include the coronary sinus, superior vena cava, fossa ovalis, and various ligaments such as the ligamentum arteriosum and ligamentum venosum. The allantois gives rise to the urachus, while the umbilical artery becomes the medial umbilical ligaments and the umbilical vein becomes the ligamentum teres hepatis inside the falciform ligament. Overall, cardiovascular embryology is a complex process that involves the differentiation and development of various structures that ultimately form the mature heart.